4.6 Article

Age at menarche and lung function: a Mendelian randomization study

期刊

EUROPEAN JOURNAL OF EPIDEMIOLOGY
卷 32, 期 8, 页码 701-710

出版社

SPRINGER
DOI: 10.1007/s10654-017-0272-9

关键词

Mendelian randomization; Menarche; Puberty; Lung function; FVC; FEV1/FVC

资金

  1. European Union [633212]
  2. MRC programme Grant [G1000861]
  3. UK Medical Research Council [G0902125]
  4. Medical Research Council (MRC) [MC_PC_12010, G0501942, G0902313]
  5. National Institute for Health Research (NIHR)
  6. Academy of Finland [104781, 120315, 129269, 1114194, 24300796]
  7. Academy of Finland (Center of Excellence in Complex Disease Genetics and SALVE)
  8. University Hospital Oulu
  9. Biocenter
  10. University of Oulu, Finland [75617]
  11. NHLBI through the STAMPEED program [5R01HL087679-02, 1RL1MH083268-01]
  12. NIH/NIMH [5R01MH63706:02]
  13. ENGAGE Project
  14. EU FP7 EurHEALTHAgeing [277849]
  15. Medical Research Council, UK [G0500539, G0600705, G1002319]
  16. MRC
  17. Centenary Early Career Award
  18. DynaHEALTH action [H2020-633595]
  19. academy of Finland EGEA-project
  20. Biocentrum Helsinki
  21. European Commission [018996]
  22. Fondo de Investigacion Sanitaria [91/0016-060-05/E, 92/0319, 93/0393, 97/0035-01, 99/0034-01, 99/0034-02]
  23. Hospital General de Albacete
  24. Hospital General Ramon Jimenez
  25. Consejeria de Sanidad del Principado de Asturias
  26. CIRIT [1997SGR 00079, 1999SGR 00241]
  27. Servicio Andaluz de Salud
  28. SEPAR
  29. Public Health Service [R01 HL62633-01]
  30. RCESP [C03/09]
  31. Red RESPIRA [C03/011]
  32. Basque Health Department
  33. Swiss National Science Foundation
  34. Swiss Federal Office for Education and Science
  35. Swiss National Accident Insurance Fund (SUVA)
  36. GSF-National Research Centre for Environment and Health
  37. Deutsche Forschungsgemeinschaft (DFG) [FR 1526/1-1, MA 711/4-1]
  38. Programme Hospitalier de Recherche CliniqueDRC de Grenoble [2610]
  39. Ministry of Health, Direction de la Recherche Clinique
  40. Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante
  41. CHU de Grenoble
  42. Comite des Maladies Respiratoires de l'Isere
  43. UCB-Pharma (France)
  44. Aventis (France)
  45. Glaxo France
  46. Estonian Science Foundation
  47. AsthmaUK
  48. UK Medical Research Council
  49. Wellcome Trust [102215/2/13/2]
  50. European Union [633212]
  51. MRC programme Grant [G1000861]
  52. UK Medical Research Council [G0902125]
  53. Medical Research Council (MRC) [MC_PC_12010, G0501942, G0902313]
  54. National Institute for Health Research (NIHR)
  55. Academy of Finland [104781, 120315, 129269, 1114194, 24300796]
  56. Academy of Finland (Center of Excellence in Complex Disease Genetics and SALVE)
  57. University Hospital Oulu
  58. Biocenter
  59. University of Oulu, Finland [75617]
  60. NHLBI through the STAMPEED program [5R01HL087679-02, 1RL1MH083268-01]
  61. NIH/NIMH [5R01MH63706:02]
  62. ENGAGE Project
  63. EU FP7 EurHEALTHAgeing [277849]
  64. Medical Research Council, UK [G0500539, G0600705, G1002319]
  65. MRC
  66. Centenary Early Career Award
  67. DynaHEALTH action [H2020-633595]
  68. academy of Finland EGEA-project
  69. Biocentrum Helsinki
  70. European Commission [018996]
  71. Fondo de Investigacion Sanitaria [91/0016-060-05/E, 92/0319, 93/0393, 97/0035-01, 99/0034-01, 99/0034-02]
  72. Hospital General de Albacete
  73. Hospital General Ramon Jimenez
  74. Consejeria de Sanidad del Principado de Asturias
  75. CIRIT [1997SGR 00079, 1999SGR 00241]
  76. Servicio Andaluz de Salud
  77. SEPAR
  78. Public Health Service [R01 HL62633-01]
  79. RCESP [C03/09]
  80. Red RESPIRA [C03/011]
  81. Basque Health Department
  82. Swiss National Science Foundation
  83. Swiss Federal Office for Education and Science
  84. Swiss National Accident Insurance Fund (SUVA)
  85. GSF-National Research Centre for Environment and Health
  86. Deutsche Forschungsgemeinschaft (DFG) [FR 1526/1-1, MA 711/4-1]
  87. Programme Hospitalier de Recherche CliniqueDRC de Grenoble [2610]
  88. Ministry of Health, Direction de la Recherche Clinique
  89. Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante
  90. CHU de Grenoble
  91. Comite des Maladies Respiratoires de l'Isere
  92. UCB-Pharma (France)
  93. Aventis (France)
  94. Glaxo France
  95. Estonian Science Foundation
  96. AsthmaUK
  97. UK Medical Research Council
  98. Wellcome Trust [102215/2/13/2]
  99. [HEALTH-F4-2007-201413]
  100. Medical Research Council [G0902313, G0601361, MR/M022501/1, G0600705, G0501942, G1000861, G9815508, MC_PC_12010, G0902125, G1002319, MR/N011317/1, MC_PC_15018, MC_UU_12013/1] Funding Source: researchfish
  101. National Institute for Health Research [ACF-2013-21-018] Funding Source: researchfish
  102. MRC [G1000861, G0601361, MC_PC_12010, MR/M022501/1, G0501942, G1002319, MR/N011317/1, G0600705, MC_UU_12013/1, G0902313] Funding Source: UKRI

向作者/读者索取更多资源

A trend towards earlier menarche in women has been associated with childhood factors (e.g. obesity) and hypothesised environmental exposures (e.g. endocrine disruptors present in household products). Observational evidence has shown detrimental effects of early menarche on various health outcomes including adult lung function, but these might represent spurious associations due to confounding. To address this we used Mendelian randomization where genetic variants are used as proxies for age at menarche, since genetic associations are not affected by classical confounding. We estimated the effects of age at menarche on forced vital capacity (FVC), a proxy for restrictive lung impairment, and ratio of forced expiratory volume in one second to FVC (FEV1/FVC), a measure of airway obstruction, in both adulthood and adolescence. We derived SNP-age at menarche association estimates for 122 variants from a published genome-wide meta-analysis (N = 182,416), with SNP-lung function estimates obtained by meta-analysing three studies of adult women (N = 46,944) and two of adolescent girls (N = 3025). We investigated the impact of departures from the assumption of no pleiotropy through sensitivity analyses. In adult women, in line with previous evidence, we found an effect on restrictive lung impairment with a 24.8 mL increase in FVC per year increase in age at menarche (95% CI 1.8-47.9; p = 0.035); evidence was stronger after excluding potential pleiotropic variants (43.6 mL; 17.2-69.9; p = 0.001). In adolescent girls we found an opposite effect (-56.5 mL; -108.3 to -4.7; p = 0.033), suggesting that the detrimental effect in adulthood may be preceded by a short-term post-pubertal benefit. Our secondary analyses showing results in the same direction in men and boys, in whom age at menarche SNPs have also shown association with sexual development, suggest a role for pubertal timing in general rather than menarche specifically. We found no effect on airway obstruction (FEV1/FVC).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据